
Standard Half-Life (SHL) Factor Therapy
This video gives a quick introduction to standard half-life (SHL) clotting factor replacement therapy. Learn more about different treatment options
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other patient advocacy and scientific organizations from the global bleeding disorders community to an informational webinar on the recent milestone revisions to the World Health Organization (WHO) Essential Medicines List (EML). The objectives of this webinar were to provide information on these critical changes to WHO EML brining it more up-to-date with the international clinical guidelines for hemophilia and von Willebrand Disease, the advocacy carried out by the WFH in collaboration with key partners and stakeholders from the bleeding disorders community, and what does this mean in practice for our community. During the webinar participants heard from WFH President, Cesar Garrido, WFH Vice President Medical, Glenn Pierce, MD, PhD and Brian O’Mahony, Chief Executive, Irish Haemophilia Society, followed by a Q&A session.
Date recorded: October 17th, 2025.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

This video gives a quick introduction to standard half-life (SHL) clotting factor replacement therapy. Learn more about different treatment options

This fact sheet contains commonly asked questions and more information on standard half-life (SHL) and extended half-life (EHL) clotting factor
In these sessions from the WFH 2022 World Congress, listen to Kate Khair, Luke Pembroke, Louis Marlow, Andrew Selvaggi, Robert

In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the

In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel

In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing